menu
    • menu
    [{"orgOrder":0,"company":"Taiba Healthcare","sponsor":"Insmed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Agreement","leadProduct":"Amikacin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Taiba Healthcare","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension for Inhalation","sponsorNew":"Taiba Healthcare \/ Taiba Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Taiba Healthcare \/ Taiba Healthcare"},{"orgOrder":0,"company":"Taiba Healthcare","sponsor":"X4 Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Agreement","leadProduct":"Mavorixafor","moa":"C-X-C chemokine receptor type 4","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Taiba Healthcare","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Taiba Healthcare \/ Taiba Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Taiba Healthcare \/ Taiba Healthcare"},{"orgOrder":0,"company":"Taiba Healthcare","sponsor":"Aspargo Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"Sildenafil Citrate","moa":"Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Taiba Healthcare","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Taiba Healthcare \/ Taiba Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Taiba Healthcare \/ Taiba Healthcare"},{"orgOrder":0,"company":"Taiba Healthcare","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Agreement","leadProduct":"Patisiran","moa":"Transthyretin mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Taiba Healthcare","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Taiba Healthcare \/ Taiba Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Taiba Healthcare \/ Taiba Healthcare"},{"orgOrder":0,"company":"Taiba Healthcare","sponsor":"Elevar Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"OMAN","productType":"Cytotoxic Drug","year":"2020","type":"Agreement","leadProduct":"Paclitaxel","moa":"||Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Taiba Healthcare","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Taiba Healthcare \/ Elevar Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Taiba Healthcare \/ Elevar Therapeutics"},{"orgOrder":0,"company":"Taiba Healthcare","sponsor":"Immuneel Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Cell & Gene Therapy","year":"2024","type":"Financing","leadProduct":"Varnimcabtagene Autoleucel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Taiba Healthcare","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Taiba Healthcare \/ Taiba Healthcare","highestDevelopmentStatusID":"8","companyTruncated":"Taiba Healthcare \/ Taiba Healthcare"}]

    Find Clinical Drug Pipeline Developments & Deals by Taiba Healthcare

    Menu

    Taiba Healthcare

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Taiba Healthcare

                            Oman arrow
                            Luxepack
                            Not Confirmed

                            Taiba Healthcare

                            Oman arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mavorixafor

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Approved FDF

                            Recipient : X4 Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            X4 Pharma, Taiba Rare Ink Xolremdi Deal for WHIM in Middle East

                            Details : Under the agreement, Taiba will be responsible for the distribution and commercialization of Xolremdi (mavorixafor), an oral, once-daily treatment for WHIM syndrome in MENA region.

                            Product Name : Xolremdi

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            February 19, 2025

                            Lead Product(s) : Mavorixafor

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Approved FDF

                            Recipient : X4 Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Taiba Healthcare

                            Oman arrow
                            Luxepack
                            Not Confirmed

                            Taiba Healthcare

                            Oman arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Varnimcabtagene Autoleucel

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Immuneel Therapeutics

                            Deal Size : $12.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Taiba Makes Strategic Investment in Immuneel Therapeutics to Advance CAR T-cell Research

                            Details : The intended to advance CAR T-cell research development of Phase 2 trial for CD19 CAR-T IMN-003A (varnimcabtagene autoleucel) targeting B-cell malignancies, including leukemia and lymphoma.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            July 30, 2024

                            Lead Product(s) : Varnimcabtagene Autoleucel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Immuneel Therapeutics

                            Deal Size : $12.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Taiba Healthcare

                            Oman arrow
                            Luxepack
                            Not Confirmed

                            Taiba Healthcare

                            Oman arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sildenafil Citrate

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved FDF

                            Recipient : Aspargo Laboratories

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Aspargo’s Global Footprint Grows With Middle East Expansion, Disrupting the Erectile Dysfunction Market With...

                            Details : The license grants Taiba the exclusive right and license to market, promote, and distribute Viagra as Sildenafil Spray in the territory described in the license, which covers Saudi Arabia, Kuwait, the United Arab Emirates, Qatar, Bahrain, Oman, Lebanon, ...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 04, 2022

                            Lead Product(s) : Sildenafil Citrate

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved FDF

                            Recipient : Aspargo Laboratories

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Taiba Healthcare

                            Oman arrow
                            Luxepack
                            Not Confirmed

                            Taiba Healthcare

                            Oman arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amikacin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Recipient : Insmed

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Taiba Middle East Announces a Commercialization and Distribution Agreement With Insmed for ARIKAYCE in the Cou...

                            Details : Under the terms of the agreement, taiba will be responsible for the named patient supply program with intent to commercialize ARIKAYCE in the region following receipt of marketing authorization(s) in the territory.

                            Product Name : Arikayce

                            Product Type : Antibiotic

                            Upfront Cash : Undisclosed

                            June 14, 2021

                            Lead Product(s) : Amikacin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Recipient : Insmed

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Taiba Healthcare

                            Oman arrow
                            Luxepack
                            Not Confirmed

                            Taiba Healthcare

                            Oman arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paclitaxel,Carboplatin

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Elevar Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Elevar Therapeutics and Taiba Middle East FZ LLC Partner to Commercialize Apealea® in the Middle East and Nor...

                            Details : Tiba will be responsible for managing named-patient requests through which physicians can legally and ethically prescribe Apealea for patients prior to commercial availability, commercialize and distribute the product throughout the Middle East and North...

                            Product Name : Apealea

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Undisclosed

                            October 05, 2020

                            Lead Product(s) : Paclitaxel,Carboplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Elevar Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Taiba Healthcare

                            Oman arrow
                            Luxepack
                            Not Confirmed

                            Taiba Healthcare

                            Oman arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Patisiran

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Recipient : Alnylam Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Alnylam Pharmaceuticals and Taiba Group Partner to Commercialize RNAi Therapeutics in the Gulf States

                            Details : The distribution agreement is focused on both ONPATTRO® and GIVLAARI®, the first-ever commercialized RNAi therapeutics, as well as another late-stage therapy in development for Primary Hyperoxaluria Type 1.

                            Product Name : Onpattro

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            July 08, 2020

                            Lead Product(s) : Patisiran

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Recipient : Alnylam Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth